Clinical Trial Update: Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation study evaluating intravitreal vMCO-I for safety and tolerability in advanced retinitis pigmentosa has completed (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Degeneration
• Retinal Diseases
• Retinitis Pigmentosa

Drugs mentioned

• vMCO-I

Snippet

Sponsor: Nanoscope Therapeutics Inc. | Conditions: Retinitis Pigmentosa, Retinal Diseases | Phase 1, Phase 2 | Status: COMPLETED